North America In Vitro Diagnostics (IVD) Market in Emerging Countries, 2025-2035
The North America In Vitro Diagnostics (IVD) market in emerging countries is poised for notable expansion, driven by advances in automation, growing diagnostic needs, and increasing adoption in clinical settings. The market spans technology types including immunoassays, molecular diagnostics, and clinical chemistry, offering solutions for infectious diseases, oncology, cardiology, and more. Growth is fueled by rising healthcare expenditures, demand for rapid diagnostics, technological innovation, and supportive regulatory environments. Key players are investing in strategic partnerships and R&D to capture market share, while providers and clinical laboratories are leveraging new platforms for enhanced patient care. This dynamic environment is shaping the market trend and creating new opportunities for growth and investment.
Latest Market Dynamics
Key Drivers
- Rising prevalence of chronic and infectious diseases demanding early and precise diagnostics, as reflected in recent product launches by Abbott Laboratories targeting rapid infectious disease identification in 2025.
- Technological advances in molecular diagnostics and digital platforms, exemplified by Thermo Fisher Scientific's AI-powered diagnostic solutions rolled out in early 2025.
Key Trends
- Widespread adoption of point-of-care testing (POCT) devices, as Siemens Healthineers boosted its POCT segment with a novel cardiac biomarker panel launched in the first half of 2025.
- Integrative digital health solutions, such as Roche Diagnostics' cloud-based diagnostic data management platform released in March 2025, enhancing interoperability and real-time access to patient diagnostic information.
Key Opportunities
- Expanding access to IVD technologies in smaller clinical and research laboratories backed by bioMérieux S.A.'s newly established network of distribution partnerships across emerging North American markets in 2025.
- Growth of oncology and genetic diagnostics driven by Illumina’s strategic collaboration with major cancer centers in Mexico and Canada, announced in February 2025.
Key Challenges
- Persistent gaps in reimbursement policies and misconceptions regarding diagnostic accuracy, challenging newer players such as QIAGEN N.V. to demonstrate value and negotiate wider coverage in 2025.
- Insufficient standardization in test quality across borders, with Becton, Dickinson and Company investing in technician training and standardized reagent supply chains starting May 2025.
Key Restraints
- High costs associated with advanced testing platforms, leading to adoption hesitancy among smaller clinical setups, as reported by Sysmex Corporation in April 2025.
- Regulatory complexity and varying approval cycles across North American emerging country markets, recently highlighted by Ortho Clinical Diagnostics’ delays in approval filings in Q2 2025.
North America IVD Market Share by Type, 2025
Reagents & kits command the largest share in the IVD market by type, owing to their centrality in diagnostic workflows and ongoing consumable demand. Instruments represent significant value due to equipment upgrades in hospitals and labs, while software & services are on an upward trend with digital integration.
North America IVD Market Share by Application, 2025
Infectious diseases diagnostics hold the dominant position in application share, propelled by intensified screening and pandemic preparedness. Oncology applications are rapidly growing due to rising cancer incidence and precision medicine trends, while cardiology remains crucial for early risk assessment.
North America IVD Market Revenue (USD Million), 2020-2035
The market value demonstrated consistent growth from 2020 to 2025, accelerating due to post-pandemic diagnostic expansion and ongoing innovations. Revenue is projected to rise from 7,210 Million in 2021 to 13,800 Million by 2035, reflecting heightened adoption and expanding clinical applications.
North America IVD Market YOY Growth (%), 2020-2035
The year-on-year growth for the IVD market in North America's emerging countries shows a moderate to accelerating trend, peaking during the 2025-2028 period with an average YOY of 5.5-7%. Growth momentum is attributed to expanded screening, technology updates, and increased investment in clinical diagnostics.
IVD Market Share by Region in North America, 2025
The US dominates the regional market share in North America for IVD, attributed to advanced healthcare infrastructure and R&D hubs. Canada follows with steady growth from public health initiatives, while Mexico is emerging with investment in laboratory networks and rapid diagnostics expansions.
IVD Market Player Share (%), 2025
Abbott Laboratories and Thermo Fisher Scientific collectively account for a sizable chunk of the IVD market, driven by strong R&D and comprehensive product portfolios. Roche Diagnostics remains a top performer with integrated technology solutions, while other players make up a competitive segment through targeted innovation. IVD Market Buyers Share (%), 2025
Hospitals remain the primary buyers of IVD solutions, leveraging comprehensive diagnostic systems for patient care. Clinical laboratories are the next large segment, focusing on high-throughput and efficient testing, complemented by academic settings and research laboratories investing in new assay development.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 9400 |
| Regions | United States, Canada, Mexico |
| Segments | Reagents & Kits, Instruments, Software & Services, Consumables, Calibrators & Controls, Accessories; Infectious Diseases, Oncology, Cardiology, Diabetes, Autoimmune Diseases, Nephrology |
| Players | Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthineers AG, Bio-Rad Laboratories Inc., bioMérieux S.A., Becton Dickinson and Company, Sysmex Corporation, Ortho Clinical Diagnostics, QIAGEN N.V., Quest Diagnostics Incorporated, Illumina Inc., Agilent Technologies Inc., PerkinElmer Inc. |
Key Recent Developments
- June 2024: Abbott Laboratories announced the launch of an ultra-fast molecular diagnostic system for infectious diseases tailored for emerging North American markets.
- July 2024: Thermo Fisher Scientific unveiled an AI-enabled data analytics suite at AACC 2024, targeting integrated lab workflows.
- August 2024: Roche Diagnostics received regulatory clearance for its cloud-based diagnostic software platform expansion into Mexico.
- September 2024: Illumina partnered with leading cancer institutes in Canada and Mexico to pilot next-generation sequencing for oncology diagnostics.
- October 2024: Siemens Healthineers released a new cardiac POCT panel across select North American hospital networks.
